{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:45:46Z","timestamp":1788860746190,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The anti-fracture efficacy of most osteoporosis drugs is assessed in trials of up to 3\u00a0yr duration. However, treatment of osteoporosis is required long-term, so it is important to know whether effectiveness of treatment changes over time. To date, this information has only been available from open extensions of the treatment groups from clinical trials. Such data are subject to selective loss of frailer patients from the cohort, and no placebo comparator group is available to permit reliable measurement of anti-fracture efficacy. The 6-yr Auckland zoledronate RCT administered zoledronate or placebo every 18\u00a0mo to 2000 osteopenic women aged &amp;gt;65\u00a0yr. It is longer than most osteoporosis trials, and only 3.6% of participants withdrew or were lost to follow-up. Therefore, anti-fracture efficacy can be validly compared between the first and second halves of this study. There were 178 non-vertebral fractures in the placebo group and 108 in the zoledronate group (excluding fractures of the hands, feet, and face). Fracture rates per 1000 women-years in the placebo group were 28 (95% CI 23, 35) and 32 (26, 40) in years 1-3 and years 4-6, respectively. In the zoledronate group, fracture rates were 23 (18, 30) and 13 (9, 18) per 1000 women-years in the first and second halves of the study. The rate ratios for non-vertebral fractures were 0.83 (0.60, 1.14) in years 1-3, and 0.40 (0.27, 0.58) in years 4-6 (between-period comparison, p\u2009&amp;lt;\u2009.05). Rate ratios for total fragility fractures, which include vertebral fractures also, showed a similar pattern: years 1-3, 0.76 (0.56, 1.02) and years 4-6, 0.39 (0.29, 0.53). These findings suggest that the efficacy for non-vertebral fracture prevention of anti-resorptive drugs has been underestimated because of the short-term evaluation of their effects. Further, it indicates that longer term treatment with these drugs may yield greater benefit to patients.<\/jats:p>","DOI":"10.1093\/jbmr\/zjag012","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:38:13Z","timestamp":1768999093000},"page":"945-950","source":"Crossref","is-referenced-by-count":3,"title":["Decreased nonvertebral fracture incidence with zoledronate use for &amp;gt;3\u00a0years: post hoc analysis of a Randomized Controlled Trial"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5458","authenticated-orcid":false,"given":"Ian R","family":"Reid","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland , Auckland , 1142,","place":["New Zealand"]},{"name":"Departments of Endocrinology and Radiology, Auckland District Health Board , Auckland , 1023,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M","family":"Horne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland , Auckland , 1142,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borislav","family":"Mihov","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland , Auckland , 1142,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Bastin","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology and Radiology, Auckland District Health Board , Auckland , 1023,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-2674","authenticated-orcid":false,"given":"Mark J","family":"Bolland","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland , Auckland , 1142,","place":["New Zealand"]},{"name":"Departments of Endocrinology and Radiology, Auckland District Health Board , Auckland , 1023,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0412-3203","authenticated-orcid":false,"given":"Gregory D","family":"Gamble","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland , Auckland , 1142,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2026082903273045700_ref1","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"key":"2026082903273045700_ref2","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"key":"2026082903273045700_ref3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S2213-8587(24)00003-2","article-title":"Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years","volume":"12","author":"Reid","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026082903273045700_ref4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2026082903273045700_ref5","first-page":"25","volume-title":"Bisphosphonates for Treating Osteoporosis","author":"National Institute for Health and Care Excellence","year":"2017"},{"issue":"10","key":"2026082903273045700_ref6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jama.2025.6003","article-title":"Osteoporosis: a review","volume":"334","author":"Morin","year":"2025","journal-title":"JAMA"},{"key":"2026082903273045700_ref7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"2026082903273045700_ref8","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"2026082903273045700_ref9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2026082903273045700_ref10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture prevention with infrequent zoledronate in women 50 to 60 years of age","volume":"392","author":"Bolland","year":"2025","journal-title":"N Engl J Med"},{"key":"2026082903273045700_ref11","article-title":"Anti-fracture efficacy of 5- or 10- yearly zoledronate in women aged 50-60y: secondary analyses of a randomized trial","author":"Bolland","journal-title":"J Clin Endocrinol Metab"},{"key":"2026082903273045700_ref12","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2026082903273045700_ref13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"2026082903273045700_ref14","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2026082903273045700_ref15","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment - the fracture intervention trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"2026082903273045700_ref16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjag012\/66533997\/zjag012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/9\/945\/66533997\/zjag012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/9\/945\/66533997\/zjag012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:27:40Z","timestamp":1787988460000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/41\/9\/945\/8436869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,1,22]]},"published-print":{"date-parts":[[2026,8,21]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjag012","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,1,22]]}}}